血管抑制剂
医学
临床试验
血管内皮生长因子受体
药理学
贝伐单抗
内科学
化疗
出处
期刊:Current Drug Targets
[Bentham Science]
日期:2020-09-18
卷期号:21 (12): 1194-1200
被引量:13
标识
DOI:10.2174/1389450121666200428101738
摘要
: This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. : Results of clinical trials and the advantages of each drug compared to the available molecules are discussed in detail.
科研通智能强力驱动
Strongly Powered by AbleSci AI